In New York, comparator evidence is common in discrimination cases but rarely used in employment contract disputes. Courts ...

In a new observational study published in Cancer, commonly prescribed chronic medications did not affect the efficacy of ...

A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...

Despite randomised clinical trials (RCTs) being the gold standard for drug approval studies, the shift towards precision medicine has increased the use of single-arm trials (SATs). SATs lack results ...

Managed care organizations must prioritize dextromethorphan-bupropion based on sustained efficacy, improved remission rates, ...

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 ...

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...

Strong adherence and safety. Long-term cost savings depend heavily on patient adherence. While twice-daily dosing may pose some risk, its safety profile and novel mechanism—targeting NMDA and sigma-1 ...

Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral reboundsActivity shown in Paxlovid®-ineligible ...

Among patients with psoriasis who have active or recent cancer, biologic therapies show similar cancer progression or recurrence and serious infection rates compared with conventional systemic agents.

Where a college professor failed to plead facts making its plausible that his non-selection for tenure was for discriminatory ...